PE firms, $500M–$10B AUM
PE Advisory
Buy-side diligence. Market thesis. Portfolio AI strategy.
BluCascadia provides specialized advisory for PE firms investing in healthcare IT, covering the full diligence lifecycle — from thesis development through market assessment, competitive landscape, management evaluation, and post-acquisition strategy.
We combine proprietary real-time intelligence (IE2 monitors 60+ healthcare IT companies) with 40+ years of combined operating experience across the full healthcare IT spectrum. This means PE-speed diligence: typically 2–3 weeks instead of 2–3 months, without external consultant overhead. Every PE engagement now includes an AI lens — assessing target company AI maturity, competitive exposure to AI-native disruptors, and portfolio-wide AI value creation opportunities.
Core engagements:
- Buy-side due diligence for healthcare IT platform acquisitions
- Market thesis development and sector mapping
- Competitive landscape and threat assessment
- Management team evaluation and CEO advisory
- Post-acquisition strategic roadmap and 100-day planning
- AI maturity assessment and competitive exposure analysis
- Portfolio company AI strategy and value creation planning
Why BluCascadia:
- Principal-led engagement on every mandate (no delegation)
- Proprietary intelligence (IE2) for real-time competitive landscape visibility
- Five-time CEO and President operating experience across the healthcare spectrum — payer, ambulatory, acute, post-acute, and RCM
- Specialist network available for tactical execution (no external markup)
- Compressed timeline grounded in pre-built intelligence, not day-one research